
Dr Mehra discussed HPV-positive oropharyngeal cancer, focusing on balancing high cure rates while minimizing toxicity through careful patient selection.

Dr Mehra discussed HPV-positive oropharyngeal cancer, focusing on balancing high cure rates while minimizing toxicity through careful patient selection.

Findings from the PARADIGM trial suggest that the use of azacitidine and venetoclax could replace intensive chemotherapy in younger, fit patients with acute myeloid leukemia.

Dr Dale Shepard of Cleveland Clinic discusses the PYNNACLE trial results for rezatapopt, the first successful small-molecule reactivation of mutant p53.

Dr Nicolas Girard discusses PALOMA-2 at ELCC 2026, highlighting the 85% ORR and safety of subcutaneous amivantamab plus lazertinib in first-line EGFR+ NSCLC.

As one of the rare subtypes of renal cell carcinoma, renal medullary carcinoma presents with some distinct signs: male, Black, between 12 and 45 years of age, sickle cell trait, and a mass in the right kidney.

The phase 3 ATOMIC trial is changing the way we treat stage III dMMR colon cancer. In this video, Dr. Sinicrope breaks down the landmark findings, and explains why this trial is now considered practice changing.

During the 2026 NCCN Annual Conference, Sandy Srinivas, MD, emphasized that HRR mutation testing in advanced prostate cancer is underutilized.

Learn how age, TP53 risk, and lifestyle shape choosing fixed-duration vs continuous CLL therapy, with shared decision tips from Dr Lamanna.

Historically, treating patients with urothelial carcinoma who were considered cisplatin-ineligible due to insufficient kidney function was a signifcant unmet need; however with enfortumab vedotin entering the frontline space, these patients have another option open to them.

Benjamin Izar, MD, PhD, discusses the different cell types that affect tumor growth and immune interactions, particularly in melanoma.

Explore how Dr Sanjay Juneja and Dr Pallav Mehta leverage AI and social media to combat information overload and humanize the complex landscape of oncology.

Determining optimal treatment sequencing after frontline therapy in advanced urothelial carcinoma falls into 2 categories: traditional chemotherapy or biomarker-driven therapy.

Benjamin Izar, MD, PhD, discusses unmet needs in melanoma including drug resistance and brain and liver metastases.

Paul G. Richardson, MD, detailed the strategic integration of mezigdomide into several areas including the unmet need of post CAR T-cell therapy.

A wave of innovations across antibody-drug conjugates, synergistic combinations, and expanding biomarkers is transforming the genitourinary cancer landscape from metastatic rescue toward curative, earlier-line paradigms.

TP53 mutations represent a critical high-risk factor across myeloid diseases, necessitating immediate transplant referral as the only curative option due to the limited durability of current standard therapies such as venetoclax and hypomethylating agents.

Menin inhibitors reshape AML care, boosting targeted options for KMT2A- and NPM1-mutant disease, with promising frontline combinations beyond relapsed settings.

Frontline gastric/GE junction cancer care now pairs chemo with checkpoint inhibitors for PD-L1 CPS≥1, improving survival and spotlighting new targets like HER2 and Claudin 18.2.

Epigenetic drugs boost CD20/CD19 and T-cell activity, making bispecific antibodies hit lymphoma harder—now moving into clinical trials.

AML induction shifts beyond 7+3 as venetoclax, hypomethylating agents, and FLT3 inhibitors drive less toxic combos and oral options.

Paul G. Richardson, MD, explains the distinct potential roles and combinations including iberdomide and mezigdomide in multiple myeloma treatment.

Dr David Sallman tailors venetoclax dosing based on transplant candidacy, using 21-day induction for transplant-eligible patients followed by rapid tapering upon response.

PARADIGM data suggest azacitidine plus venetoclax improves AML event-free survival vs 7+3 with less toxicity; survival looks similar.

A patient's chronological age is no longer a barrier to allogeneic stem cell transplant in MDS/MPN, according to David Sallman, MD. Proceeding directly to transplant in patients with TP53-mutated disease may lead to optimal outcomes.

Explore why community and academic oncologists collaborate, share expertise, and deliver faster, more nuanced care for complex patients.

Estelamari Rodriguez, MD, delivers her top takeaways from the 2026 IASLC Targeted Therapies in Lung Cancer meeting.


CLL17 finds fixed-duration venetoclax regimens match continuous ibrutinib at 3 years, boosting confidence in personalized frontline CLL choices.

New DLBCL trials test bispecifics with chemo, BTK add-ons, and MRD-guided preemptive allo CAR-T to cut relapse risk.

Erica Pimenta, MD, PhD, discusses her research into using existing GLP-1 receptor agonists in dedifferentiated liposarcoma.